A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: Obinutuzumab
DRUG: MMF
DRUG: Prednisone
DRUG: Placebo
DRUG: Methylprednisolone
DRUG: Acetaminophen
DRUG: Diphenhydramine

Sponsor

Hoffmann-La Roche